WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

Raccontata datheguardian.combbc.comindependent.co.uk

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
theguardian.comStai leggendo2 mesi fa

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

originale
independent.co.uk2 mesi fa

Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims

Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 16 aprile 2026·theguardian.com

    Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

    Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

  2. giovedì 16 aprile 2026·bbc.com

    'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

    A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

bbc.com2 mesi fa

'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Leggi questa versione → originale
giovedì 16 aprile 2026·independent.co.uk

Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims

Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK